placebo for ibuzatrelvir

Phase 3

Pfizer

placebo for ibuzatrelvir is one of 4 therapeutic programs targeting COVID-19 Infection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

COVID-19 InfectionRecruiting

COVID-19 InfectionPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in COVID-19 Infection

#DrugCompanyPhaseTrials

Veklury

Gilead

Phase 3

1 2

Ibuzatrelvir

Pfizer

Phase 3

1 3

placebo for ibuzatrelvir

Pfizer

Phase 3

1 4

Pathogen-Specific Aapc

SShenzhen Geno-Immune Medical Institute

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

COVID-19 Infection

NCT07013474

Clinical

Trials by Indication[1]

COVID-19 Infection1 trial

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELY IMMUNOCOMPROMISED

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07013474·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for placebo for ibuzatrelvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for placebo for ibuzatrelvir. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Pfizer

placebo for ibuzatrelvir

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

COVID-19 Infection1 trial

References

Drug Info

Quick Facts

Related News